Search results for "Anti-cancer therapy"

showing 8 items of 8 documents

Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Gliobla…

2020

Background: Inevitable recurrence after radiochemotherapy is the major problem in the treatment of glioblastoma, the most prevalent type of adult brain malignancy. Glioblastomas are notorious for a high degree of intratumor heterogeneity manifest through a diversity of cell types and molecular patterns. The current paradigm of understanding glioblastoma recurrence is that cytotoxic therapy fails to target effectively glioma stem cells. Recent advances indicate that therapy-driven molecular evolution is a fundamental trait associated with glioblastoma recurrence. There is a growing body of evidence indicating that intratumor heterogeneity, longitudinal changes in molecular biomarkers and spe…

0301 basic medicineCancer ResearchCell typeMalignancylcsh:RC254-282ArticleTranscriptome03 medical and health sciencestranscriptomics0302 clinical medicineGliomaGene expressionmedicineneoplasmsTemozolomideglioblastoma stem cellsbusiness.industryglioblastomaMolecular diagnosticsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensnervous system diseases030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchgene expressionStem cellbusinesstarget anti-cancer therapymolecular pathwaysmedicine.drugrecurrent glioblastomaCancers
researchProduct

Nobiletin and xanthohumol sensitize colorectal cancer stem cells to standard chemotherapy

2021

Simple Summary Colorectal cancer stem cells (CR-CSCs) play a pivotal role in the therapy resistance and relapse of CRC patients. Herein we demonstrate that new treatment approaches comprising polymethoxyflavones and prenylflavonoids extracted from Citrus sinensis and Humulus lupulus, respectively, hamper the viability of CR-CSCs as well as synergizing with 5-fluorouracil and oxaliplatin (FOX)-based chemotherapy. Extract fractions containing Nobiletin and Xanthohumol, in combination with chemotherapy, decreased stemness properties of CR-CSCs and restrained the outgrowth of chemoresistant metastatic CR-CSCs. These data pinpoint Nobiletin and Xanthohumol as efficacious anti-cancer compounds in…

0301 basic medicinecancer stem cellCancer ResearchAnti-cancer therapyColorectal cancermedicine.medical_treatmentArticleNobiletin03 medical and health sciences0302 clinical medicineCancer stem cellSettore MED/04 - PATOLOGIA GENERALEMedicineflavonoidClonogenic assayRC254-282FlavonoidsChemotherapybusiness.industryCancer stem cellsWnt signaling pathwayXanthohumolNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell cyclemedicine.diseaseColorectal cancerOxaliplatin030104 developmental biologyOncologyflavonoids; nobiletin; xanthohumol; anti-cancer therapy; cancer stem cells; colorectal cancer; natural biofunctional molecules030220 oncology & carcinogenesisCancer researchNatural biofunctional moleculesStem cellbusinessanti-cancer therapy; cancer stem cells; colorectal cancer; flavonoids; natural biofunctional molecules; nobiletin; xanthohumolmedicine.drug
researchProduct

Polyaspartamide-Doxorubicin Conjugate as Potential Prodrug for Anticancer Therapy

2015

Purpose To synthesize a new polymeric prodrug based on ?,?- poly(N-2-hydroxyethyl)(2-aminoethylcarbamate)-d,l-aspartamide copolymer bearing amine groups in the side chain (PHEA-EDA), covalently linked to the anticancer drug doxorubicin and to test its potential application in anticancer therapy. Methods The drug was previously derivatized with a biocompatible and hydrophilic linker, leading to a doxorubicin derivative highly reactive with amino groups of PHEA-EDA. The PHEAEDA- DOXO prodrug was characterized in terms of chemical stability. The pharmacokinetics, biodistribution and cytotoxicity of the product was investigated in vitro and in vivo on human breast cancer MCF-7 and T47D cell lin…

BiodistributionPolymeric prodrugPharmaceutical ScienceBreast NeoplasmsMice SCIDpolymeric prodrugPharmacologyMice Inbred NODCell Line TumorPolyaminesmedicineSide chainAnimalsHumansProdrugsTissue Distributionantitumor activityDoxorubicinPharmacology (medical)BreastAspartamebiodistributionPharmacologyChemistryPHEA-EDAOrganic ChemistryProdrugAnticancer drugPolyaspartamideDoxorubicinMCF-7 CellsMolecular MedicineFemaleAmine gas treatingantitumor activity; biodistribution; doxorubicin; PHEA-EDA; polymeric prodruganti-cancer therapymedicine.drugConjugateBiotechnology
researchProduct

Cancer cell targeting by CAR-T cells: A matter of stemness

2022

Chimeric antigen receptor (CAR)-T cell therapy represents one of the most innovative immunotherapy approaches. The encouraging results achieved by CAR-T cell therapy in hematological disorders paved the way for the employment of CAR engineered T cells in different types of solid tumors. This adoptive cell therapy represents a selective and efficacious approach to eradicate tumors through the recognition of tumor-associated antigens (TAAs). Binding of engineered CAR-T cells to TAAs provokes the release of several cytokines, granzyme, and perforin that ultimately lead to cancer cells elimination and patient’s immune system boosting. Within the tumor mass a subpopulation of cancer cells, known…

CAR-T cell therapycancer stem cellAnti-cancer therapySettore MED/50 - Scienze Tecniche Mediche ApplicateTumor MicroenvironmentImmunotherapySettore MED/46 - Scienze Tecniche Di Medicina Di Laboratorio
researchProduct

Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by …

2010

The mdm2 oncogene product, MDM2, is an ubiquitin protein ligase that inhibits the transcriptional activity of the tumor suppressor p53 and promotes its degradation. About 50% of all human cancers present mutations or deletions in the TP53 gene. In the remaining half of all human neoplasias that express the wild-type protein, aberrations of p53 regula- tors, such as MDM2, account for p53 inhibition. For this reason, designing small-molecule inhibitors of the p53-MDM2 protein-protein interaction is a promising strategy for the treatment of cancers retaining wild-type p53. The development of inhibitors has been challenging. Although many small-molecule MDM2 inhibitors have shown potent in vitr…

IndolesTumor suppressor geneAntineoplastic AgentsMolecular Dynamics SimulationBioinformaticsBiochemistryGene productNeoplasmsDrug DiscoverymedicineHumansImidazolinesMolecular Modeling New Drugs for Anti-Cancer Therapy p53-MDM2 InteractionPharmacologyBenzodiazepinonesbiologyOncogeneOrganic ChemistryCancerProto-Oncogene Proteins c-mdm2medicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeUbiquitin ligaseOxindolesProtein Structure TertiaryDrug Designbiology.proteinCancer researchMolecular MedicineMdm2PharmacophoreTumor Suppressor Protein p53Current medicinal chemistry
researchProduct

The role of heat shock proteins in neoplastic processes and the research on their importance in the diagnosis and treatment of cancer

2021

Heat shock proteins (HSPs) are chaperones with highly conservative primary structure, necessary in the processes of protein folding to the most energetically advantageous conformation and maintaining their stability. HSPs perform a number of important functions in various cellular processes and are capable of modulating pathophysiological conditions at the cellular and systemic levels. An example is the high level of HSP expression in neoplastic tissues, which disrupts the apoptosis of transformed cells and promotes the processes of proliferation, invasion, and metastasis. In addition, an increasing amount of information is appearing about the participation of HSPs in the formation of multi…

Review PaperResearch groupsbusiness.industryDisease progressionRapoptosisCancermedicine.diseaseanti-cancer therapy.Cancer treatmentMetastasisOncologyHeat shock proteinheat shock proteinsmedicineCancer researchMedicineNeoplastic ProcessescancerRadiology Nuclear Medicine and imagingProtein foldingbusinessanti-cancer therapyContemporary Oncology
researchProduct

Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment

2014

Cancer is one of the most urgent health issues of today. According to WHO, the number of cancer cases is expected to increase by 75% in the next two decades (1). Despite some remarkable achievements in the fields of cancer prevention and early detection, the goal of developing effective anti-cancer therapies still remains unmet. Tumor recurrence due to treatment resistance is the most common cause of death from cancer. Delineating cellular and molecular mechanisms underlying tumor recurrence is of prime importance for the ability to improve the efficacy of existing therapies and develop new strategies to cancer treatment.

cancer stem cellsCancer Researchmedicine.medical_specialtytumor clones selectionEarly detectionintratumor heterogeneityBioinformaticslcsh:RC254-282Intratumor heterogeneityCancer stem cellmedicinecancerTreatment resistanceIntensive care medicineCancer preventionbusiness.industryintratumor spatiotemporal patternsCancerOpinion Articlelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetumor recurrenceCancer treatmentTumor recurrenceOncologybusinessanti-cancer therapyFrontiers in Oncology
researchProduct

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

2017

Cancer can be considered an aberrant organ with a hierarchical composition of different cell populations. The tumor microenvironment, including the immune cells and related cytokines, is crucial during all the steps of tumor development. In particular, type I and II interferons are involved in a plethora of mechanisms that regulate immune responses in cancer, thus balancing immune escape versus immune surveillance. Interferons are involved in both the direct and indirect regulation of cancer cell proliferation and metastatic potential. The mutational background of genes involved in interferons signaling could serve as a prognostic biomarker and a powerful tool to screen cancer patients elig…

lcsh:Immunologic diseases. Allergy0301 basic medicineColorectal cancerCellImmunologyContext (language use)ReviewBiology03 medical and health sciencesImmune systemInterferonmedicineAnti-cancer therapy; Cancer; Cancer progression; Colon; Interferon; Melanoma; Tumor immunology; Immunology and Allergy; ImmunologymelanomaImmunology and Allergycancertumor immunologyTumor microenvironmentcolonMelanomaCancerinterferonmedicine.diseasecancer progression030104 developmental biologymedicine.anatomical_structureImmunologyCancer researchlcsh:RC581-607anti-cancer therapymedicine.drugFrontiers in Immunology
researchProduct